Skip to main content
Clinical Trials/CTRI/2018/06/014416
CTRI/2018/06/014416
Active, not recruiting
Phase 1

The levels of matrix metalloproteinase(MMP-9) as a prognostic biomarker for the outcome of pulpotomy in mature permanent teeth with symptomatic irreversible pulpitis- A clinical prospective study.

Center for Dental Education and Research0 sites0 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Center for Dental Education and Research

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1\-Healthy patient of either gender belonging to 15\-35 years of age group.
  • 2\-Mandibular molar teeth with established clinical diagnosis of symptomatic irreversible pulpitis without periapical rarefaction
  • 3\-Positive response to cold and electric pulp tests
  • 4\-Teeth with restorable carious lesions

Exclusion Criteria

  • 1\-Teeth with immature roots.
  • 2\-Teeth with cracks, cusp fractures, Subgingival caries.
  • 3\-Teeth with poor periodontal health, probing pocket depth \>3mm, furcation involvement and radiographic horizontal or vertical interdental bone loss.
  • 4\-Presence of sinus tract or swelling or periapical pathology on an IOPA radiograph.
  • 5\-Patients with systemic conditions which could compromise the healing.
  • 6\-Patients not willing to participate in the study.

Investigators

Sponsor
Center for Dental Education and Research

Similar Trials